安罗替尼在肺癌治疗中的研究进展  

Research progress of anlotinib in the treatment of lung cancer

作　　者：金晨星 赵翌[1] 刘基巍[1] JIN Chenxing;ZHAO Yi;LIU Jiwei(Department of Oncology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China)

机构地区：[1]大连医科大学附属第一医院肿瘤科,辽宁大连116011

出　　处：《临床肿瘤学杂志》2022年第5期460-466,共7页Chinese Clinical Oncology

摘　　要：安罗替尼作为首个被中国国家食品药品监督管理局(NMPA)同时获批用于非小细胞肺癌和小细胞肺癌三线及以上治疗的多靶点小分子抗血管生成药物,为晚期肺癌后线治疗提供可能。随着不断探索,安罗替尼联合化疗、靶向治疗、免疫治疗和放疗均展现出一定的疗效,为临床应用提供更多的理论依据。因此本文就安罗替尼作用机制、在肺癌治疗中的应用、用药安全性及疗效预测因子等方面进行综述,旨在为安罗替尼的临床应用提供新的思路及选择。As the first multi-target small molecule antiangiogenic drug approved by the National Medical Products Administration(NMPA)for third line and above data of non-small cell lung cancer and small cell lung cancer,Anlotinib provides the possibility for posterior line treatment of advanced lung cancer.With the continuous exploration,Anlotinib combined with chemotherapy,targeted therapy,immunotherapy and radiotherapy have shown a certain effect,which provides more theoretical basis for clinical application.Therefore,this article reviews the mechanism of action,application in the treatment of lung cancer,drug safety and efficacy predictors,in order to provide new ideas and choices for clinical application of Anlotinb.

关 键 词：肺癌 安罗替尼 抗血管治疗 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]